Found: 15
Select item for more details and to access through your institution.
Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 7, p. 1509, doi. 10.3390/jcm10071509
- By:
- Publication type:
- Article
Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Prognostication of the high-risk WM patient.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Prognostication of the High-Risk WM Patient.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2011, v. 11, n. 1, p. 127, doi. 10.3816/CLML.2011.n.028
- By:
- Publication type:
- Article
Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies.
- Published in:
- European Journal of Haematology, 2017, v. 99, n. 5, p. 409, doi. 10.1111/ejh.12923
- By:
- Publication type:
- Article
The Chronic Kidney Disease Epidemiology Collaboration cystatin C ( CKD- EPI- Cys C) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD- EPI- Cys C equations?
- Published in:
- European Journal of Haematology, 2013, v. 91, n. 4, p. 347, doi. 10.1111/ejh.12164
- By:
- Publication type:
- Article
Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era.
- Published in:
- European Journal of Haematology, 2012, v. 89, n. 1, p. 10, doi. 10.1111/j.1600-0609.2012.01784.x
- By:
- Publication type:
- Article
High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.
- Published in:
- European Journal of Haematology, 2010, v. 85, n. 2, p. 114, doi. 10.1111/j.1600-0609.2010.01466.x
- By:
- Publication type:
- Article
Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy.
- Published in:
- International Journal of Cancer, 2012, v. 131, n. 6, p. 1466, doi. 10.1002/ijc.27342
- By:
- Publication type:
- Article
Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents.
- Published in:
- International Journal of Cancer, 2012, v. 130, n. 3, p. 735, doi. 10.1002/ijc.26062
- By:
- Publication type:
- Article
Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience.
- Published in:
- 2018
- By:
- Publication type:
- journal article
The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 1, p. 34, doi. 10.1002/ajh.23577
- By:
- Publication type:
- Article
No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years.
- Published in:
- American Journal of Hematology, 2011, v. 86, n. 6, p. 479, doi. 10.1002/ajh.22027
- By:
- Publication type:
- Article
Identification of Very Low‐Risk Subgroups of Patients with Primary Mediastinal Large B‐Cell Lymphoma Treated with R‐CHOP.
- Published in:
- Oncologist, 2021, v. 26, n. 7, p. 597, doi. 10.1002/onco.13789
- By:
- Publication type:
- Article